Study Examining Exenatide Long-Acting Release in Subjects With Type 2 Diabetes

This study has been completed.

Sponsor:

Collaborator:

Eli Lilly and Company

Information provided by (Responsible Party):

Amylin Pharmaceuticals, LLC.

ClinicalTrials.gov Identifier:

NCT00103935

First received: February 17, 2005

Last updated: February 5, 2013

Last verified: February 2013

History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Study Status:	This study has been completed.
Study Completion Date:	October 2005
Estimated Primary Completion Date:	No date given

No publications provided by Amylin Pharmaceuticals, LLC.

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Fineman M, Flanagan S, Taylor K, Aisporna M, Shen LZ, Mace KF, Walsh B, Diamant M, Cirincione B, Kothare P, Li WI, MacConell L. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet. 2011 Jan 1;50(1):65-74.

To Top